Skip to content
OpenCapital
Get started

United Therapeutics UTHR Remodulin — Total revenues

Other product segments

Tyvaso DPI
$330.3M+9.2%
Orenitram
$135.6M+12.3%
Nebulized Tyvaso
$127.2M-22.3%
Unituxin
$53.6M-7.9%
Adcirca
$2.9M-51.7%

Similar metrics at other companies

Bristol-Myers Squibb logo
BMYRevlimid — Total Revenues
$349M-62.7%
Amgen logo
AMGNRepatha — Total revenues
$876M+33.5%
Bristol-Myers Squibb logo
BMYReblozyl — Total Revenues
$555M+16.1%
Amgen logo
AMGNRepatha — Total revenues
$754M+35.7%
Johnson & Johnson logo
JNJRemicade — Sales to customers (Note 9)
$422M-9.6%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's remodulin — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's remodulin — total revenues?
United Therapeutics (UTHR) reported remodulin — total revenues of $126.6M in Q1 2026.
How has United Therapeutics's remodulin — total revenues changed year-over-year?
United Therapeutics's remodulin — total revenues decreased by 8.4% year-over-year, from $138.2M to $126.6M.
What is the long-term trend for United Therapeutics's remodulin — total revenues?
Over 4 years (2021 to 2025), United Therapeutics's remodulin — total revenues has grown at a 0.6% compound annual growth rate (CAGR), from $513.7M to $526.8M.
What does remodulin — total revenues mean?
Represents the total gross or net sales generated from a specific pharmaceutical product or therapeutic line. This metric tracks the market demand and commercial adoption of the drug within its indicated patient population. It serves as a primary indicator of the product's lifecycle stage and competitive positioning in the market.